Rapacuronium

drugbox
IUPAC_name = [(2"S",3"S",5"S",8"R",9"S",10"S",13"S",14"S",16"S",17"S")-
3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-
(1-prop-2-enyl-3,4,5,6-tetrahydro-2"H"-pyridin-
1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-
1"H"-cyclopenta [a] phenanthren-17-yl] propanoate

---

imagename = Rapacuronium bromide
width = 250
CAS_number = 156137-99-4
ATC_prefix =
ATC_suffix =
PubChem = 5311398
DrugBank =
C = 37 | H = 61 | N = 2 | O = 4 | charge = +
molecular_weight = 597.891 g/mol
bioavailability = Not applicable
protein_bound = Variable
metabolism = Hydrolyzed to active metabolites
CYP system not involved
elimination_half-life = 141 minutes (mean)
excretion = Renal and fecal
pregnancy_AU =
pregnancy_US = C
legal_AU =
legal_CA =
legal_UK =
legal_status = Withdrawn (U.S)
routes_of_administration = Intravenous

Rapacuronium bromide (trade name Raplon, Organon) is a rapidly acting, non-depolarizing neuromuscular blocker used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent, it does not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm, it was withdrawn from the United States market by the manufacturer on March 27, 2001. [Shapse, Deborah (March 27, 2001). PDFlink| [http://www.fda.gov/medwatch/SAFETY/2001/raplon_DDR.pdf Voluntary Market Withdrawal] |10.8 KiB . Organon International. Retrieved on 2007-04-02.]

References